Better cancer specific survival in young small cell lung cancer patients especially with AJCC stage III

Zhang, Jingze; Shi, Fang; Zhang, Chenyue; Jiao, Qinghua; Zhu, Hui

doi:10.18632/oncotarget.16823

Cited by 15 publications

(22 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Older age, aggressive stage of the tumor, large tumor sizes, lymph node invasion and distant metastasis were correlated with poor prognosis. Consistent with that for other tumors, younger patients had relatively better survival than older patients [ 13 ]. Age was an independent prognostic indicator in one study [ 12 ].…”

Section: Discussionsupporting

confidence: 79%

Clinicopathological characteristics, treatment and prognosis of head & neck small cell carcinoma: a SEER population-based study

Yibulayin

Feng

et al. 2020

BMC Cancer

View full text Add to dashboard Cite

Background To investigate the clinicopathological characteristics of head and neck small cell carcinoma (H&NSmCC) and identify prognostic factors on the basis of the Surveillance, Epidemiology and End Results (SEER) database. Methods Total of 789 primary cases from 1973 to 2016 were included. Univariate and multivariate analyses were performed to identify independent prognostic indicators. An H&NSmCC-specific nomogram was constructed and compared with the AJCC staging system by calculating the time-dependent area under the curve (AUC) of the receiver operating characteristic (ROC) curves. Results The incidence of H&NSmCC peaked during the period of 50 to 70 years old, and the most frequent location was the salivary gland. The 5-year disease specific survival (DSS) was 27%. In the multivariate survival analysis, AJCC III + IV stage [HR = 2.5, P = 0.03, I + II stage as Ref], positive N stage [HR = 1.67, P = 0.05, negative N stage as Ref], positive M stage [HR = 4.12, P = 0.000, negative M stage as Ref] and without chemotherapy [HR = 0.56, P = 0.023, received chemotherapy as Ref] were independently associated with DSS. The H&NSmCC-specific nomogram was built based on the independent prognostic indicators. The nomogram demonstrated better predictive capacity than the AJCC staging system for 5-year DSS [(AUC: 0.75 vs 0.634; Harrell’s C-index (95% CI): 0.7(0.66–0.74) vs 0.59(0.55–0.62), P < 0.05]. Conclusion N stage, M stage, AJCC stage and chemotherapy were independent prognostic indicators included in the prognostic nomogram model, which can better predict the survival of H&NSmCC than the AJCC staging system.

show abstract

Section: Discussionsupporting

confidence: 79%

Clinicopathological characteristics, treatment and prognosis of head & neck small cell carcinoma: a SEER population-based study

Yibulayin

Feng

et al. 2020

BMC Cancer

View full text Add to dashboard Cite

show abstract

“…Similar to other types of cancer, younger patients often had much better prognosis than older patients. 10 As for SmCC of the salivary gland, a previous study also found that age was a statistically significant prognostic factor with the 5-year survival rate of younger patients (<65 years) almost 6-fold (63.5% vs 11.5%) that in older patients (≥65 years). We also observe that marital status could affect prognosis in patients with SmCC of the salivary gland in univariate analysis and this is echoed in previous data on a strong positive correlation between marriage and prognosis of cancer patients that married status had a lower HR of tumor occurrence.…”

Section: Discussionmentioning

confidence: 93%

<p>Clinicopathological Characteristics and Survival of Small Cell Carcinoma of the Salivary Gland: a Population-Based Study</p>

Bai

Zhao

Pan

2019

CMAR

View full text Add to dashboard Cite

Background: Small cell carcinoma (SmCC) of the salivary gland is rare, and the characteristics and survival are not well defined due to only case reports or case series being reported. The present study aimed to describe the clinicopathological characteristics and determine the factors associated with survival of this rare cancer. Materials and methods: A population-based study was carried out to investigate clinical characteristics and prognosis of SmCC of the salivary gland using prospectively extracted data from the Surveillance, Epidemiology and End Results (SEER) database between 1988 and 2016. Results: Totally, 198 patients with SmCC of the salivary gland were identified with an average age of 72.6±12.4 and a male to female ratio of 3.4:1. The lesions of most patients (167/198) were located in the parotid gland. The median overall survival (mOS) of all patients is 25.0 months. The 1-, 3-, 5-and 10-year survival rate was 65.7%, 40.9%, 33.0% and 22.7%, respectively. Surgery could prolong significantly the mOS by almost 17.0 months (28.0 months vs 11.0 months; P<0.01). Radiotherapy, as well as radiotherapy after surgery, could prolong the mOS (P<0.01 for both). Patients who received chemotherapy had significantly longer overall survival time than those without chemotherapy (28.0 months vs 20 months; P=0.04). The survival analysis demonstrated that old age (>72 years), lymph node (N3) and distant metastases were independent factors for poor survival, whereas radiotherapy was an independent factor for favorable survival. Conclusion: Small cell carcinoma of the salivary gland is a rare disease, and old age, lymph node and distant metastases, and radiotherapy were significantly associated with prognosis. In order to understand this disease more thoroughly, more cases with adequate information are required.

show abstract

“…Studies on IIIa/IIIb NSCLC cases not receiving MWA showed a 5-year OS range between 5 and 25%, and a CSS range between 10 and 36% (10,29–32). In the present report, the 5-year OS was 18.3%, while the 5-year CCS was 30.0%.…”

Section: Discussionmentioning

confidence: 99%

Usefulness of percutaneous microwave ablation for large non‑small cell lung cancer: A preliminary report

et al. 2019

View full text Add to dashboard Cite

The role of microwave ablation (MWA) in patients with non-small cell lung cancer (NSCLC) remains ill-defined. This retrospective study evaluated the oncological outcomes of CT-guided MWA in patients with large NSCLC. Kaplan-Meier analysis was used to evaluate overall survival (OS) and cancer-specific survival (CSS). The log-rank test was used to compare survival between patients with an NSCLC size greater or smaller than 4 cm. The likelihood of local tumor progression (LTP) was analyzed using a multivariable regression model. A total of 53 patients with 65 tumors were analyzed. The mean tumor size was 5.0±1.8 cm. At the 1-month CT scan, complete tumor ablation was observed in 44.6% of cases. In 18.5% of cases a redo-MWA session was carried out, while in 4.6%, a third MWA was necessary to obtain complete tumor necrosis. The mean follow-up was 28.1±20.6 months with a median duration of 21.5 months. The 1-year, 2-year, 3-year and 5-year OS rates were 78.2, 48.3, 34.8 and 18.3%, respectively. The median CSS was 25 months (95% CI 15.5–34.5). The 1-year, 2-year, 3-year and 5-year CSS rates were 84.3, 53.7, 42.1 and 30.0%, respectively. OS in patients with tumor size ≥4 cm was significantly lower when compared with those having smaller tumors (P=0.03). LTP was observed in 19 patients (35.8%). Incomplete tumor ablation [odds ratio (OR) 6.57; P<0.05] and tumor size ≥4 cm (OR 0.18; P<0.05) were significant independent predictors of LTP. In conclusion, CT-guided MWA may represent a useful tool in the multimodality treatment of patients with large advanced NSCLC.

show abstract

Better cancer specific survival in young small cell lung cancer patients especially with AJCC stage III

Cited by 15 publications

References 36 publications

Clinicopathological characteristics, treatment and prognosis of head & neck small cell carcinoma: a SEER population-based study

Clinicopathological characteristics, treatment and prognosis of head & neck small cell carcinoma: a SEER population-based study

<p>Clinicopathological Characteristics and Survival of Small Cell Carcinoma of the Salivary Gland: a Population-Based Study</p>

Usefulness of percutaneous microwave ablation for large non‑small cell lung cancer: A preliminary report

Contact Info

Product

Resources

About